Solara Active Pharma Sciences Limited - Neraca (Quarterly)

Solara Active Pharma Sciences Limited
IN ˙ NSEI
Talaan ng Balanse (Quarterly)

Neraca Solara Active Pharma Sciences Limited menunjukkan saldo akun perusahaan pada titik waktu tertentu. Data Neraca meliputi Aset, Aset Lancar, Aset Tetap, Properti, Pabrik dan Peralatan (PPE), Persediaan, Aset Tak Berwujud, Kewajiban, Kewajiban Lancar, Utang, Kewajiban Sewa Modal, Saham Biasa, Laba Ditahan, Saham Perbendaharaan, dan Ekuitas Pemegang Saham.

Semua angka adalah kelipatan 1,000,000.00 kecuali unit per saham.

2020
09-30
2021
03-31
2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
Cash 4,089 1,977 967 464 32 87 65 84 61 40
Change (%) -51.65 -51.10 -52.03 -93.01 169.44 -26.00 30.65 -28.08 -34.93
Assets Current 10,483 10,576 14,088 12,393 11,357 11,875 11,950 8,008 7,594 7,287
Change (%) 0.89 33.21 -12.03 -8.36 4.57 0.63 -32.99 -5.17 -4.04
Assets 25,365 26,136 30,546 29,450 28,660 28,993 28,753 23,510 22,898 22,318
Change (%) 3.04 16.87 -3.59 -2.68 1.16 -0.83 -18.24 -2.60 -2.53
Liabilities 10,574 10,208 13,886 14,178 13,654 13,968 14,091 14,144 12,011 11,349
Change (%) -3.46 36.03 2.10 -3.70 2.30 0.88 0.37 -15.08 -5.51
Equity 14,791 15,928 16,660 15,272 15,006 15,024 14,662 9,366 10,887 10,969
Change (%) 7.68 4.60 -8.33 -1.74 0.12 -2.41 -36.12 16.24 0.76
Liabilities And Stock Equity 25,365 26,136 30,546 29,450 28,660 28,993 28,753 23,510 22,898 22,318
Change (%) 3.04 16.87 -3.59 -2.68 1.16 -0.83 -18.24 -2.60 -2.53

Source: Capital IQ

Other Listings
IN:890202
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista